Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics Oxford, UK, 14 July 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’) – a pioneering biotechnology company unlocking the therapeutic potential of the regulatory genome through its proprietary 3D genomics platform – […]

Nucleome’s Michelle Morrow featured in Invivo’s Rising Leaders 2026 Decoding The Regulatory Genome To Target Increased Clinical Success – Rising Leader Michelle Morrow discusses with Ashley Yeo how her role Exploits ‘The Regulatory Genome’ For New Medicines View online here Read the PDF here

Our CEO Mark Bodmer and our VP Functional Genomics James Heward explore how decoding the dark genome is opening entirely new frontiers in drug discovery. They highlight how “understanding the non-coding regulatory regions affected by genetic variants has the potential to unlock a new era of drug discovery”. This point is underscored throughout the article […]

Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studies Oxford, UK, 16 February 2026 – Nucleome Therapeutics […]

Crispr & Genomics: turning data into confident drug discovery decisions. Click the image above to read the presentation.

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need Oxford, UK, 07 January 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a company tackling the molecular causes of inflammatory diseases through […]